A review of standard and novel therapies in Crohn’s disease

Bibliography

• PAPADAKIS KA, TARGAN SR: Current theories on the of inflammatory bowel disease. Gastroenterol Clin. North Am. (1999) 28(2):283–296.
   PubMed Web of Science ®Google Scholar
• ••A review which emphasises the heterogeneity of disease,and discusses the potential mechanisms which underlie the inappropriate immune response in CD.
   Google Scholar
• KORNBLUTH A, SACHAR DB, SALOMON P: Crohn'sdisease. In: Gastrointestinal and Liver Disease. Feldman M, Scharschmidt BF, Sleisenger MH (Eds.), WB Saunders Company, Philadelphia, USA (1998):1708–1734.
   Google Scholar
• FIOCCHI C: Inflammatory bowel disease: etiology andpathogenesis. Gastroenterology (1998) 115:182–205.
   PubMed Web of Science ®Google Scholar
• ORHOLM M, MUNKHOLM P, LANGHOLZ E, NIELSEN DH,SORENSEN IA, BINDER V: Familial occurrence of inflammatory bowel disease. N. Engl. J. Med. (1991) 324:84–88.
   PubMed Web of Science ®Google Scholar
• TYSK C, LINDBERG E, JARNEROT G, FLODERUS-MYHNEDB: Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins: a study of heritability and the influence of smoking. Gut (1988) 29(7):990–996.
   PubMed Web of Science ®Google Scholar
• SOMERVILLE KW, LOGAN RF: Smoking and Crohn'sdisease. Br. Med. J. (1982) 284:706.
   PubMedGoogle Scholar
• PIRZER U, SCHONHAAR A, FLEISCHER B, MEYER ZUMBUSCHENEFELDE KH: Reactivity of infiltrating lymphocytes with microbial antigens in Crohn's disease. Lancet (1991) 338:1238–1239.
   PubMed Web of Science ®Google Scholar
• HANAUER SB, MEYERS S: Management of Crohn's disease in adults. Am. J. Gastroenterol (1997) 92:559–566.
   PubMed Web of Science ®Google Scholar
• STEIN RB, HANAUER SB: Medical therapy for inflamma-tory bowel disease. Gastroenterol. Clin. North Am. (1999) 28 (2):297–321.
   PubMed Web of Science ®Google Scholar
• ••An excellent summary of clinical therapies which reviewsthe evidence for use of aminosalicylates, steroids, immuno-modulators, nutritional therapies and evolving treatments.
   Google Scholar
• PRESENT DH, KORELITZ BI, WISCH N et al: Treatment of's disease with 6-mercaptopurine: a long-term randomized, double-blind study. N Engl. J. Med. (1980) 302:981–987.
   PubMed Web of Science ®Google Scholar
• FEAGAN BG, ROCHON J, FEDORAK RN et al.: Methotrexate for the treatment of Crohn's disease. N Engl. J. Med. (1995) 332:292–297.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ: A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine and methotrexate. Am. J. Gastroenterol. (1996) 91:423–433.
   PubMed Web of Science ®Google Scholar
• •A review of immune modulatory therapy with attention to pharmacology, clinical evidence and practical aspects of therapy.
   Google Scholar
• HANAUER SB, SMITH MB: Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporine A. Am. J. Gastroenterol. (1993) 88:646–649.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ: Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am. J. Gastroenterol. (1997) 92:876–879
   PubMed Web of Science ®Google Scholar
• HAN PD, BURKE A, BALDASSANO RN, ROMBEAU JL, LICHTENSTEIN GR: Nutrition and inflammatory bowel disease. Gastroenterol. Clin. North Am. (19 9 9) 28(2)423–443.
   Google Scholar
• GRIFFITHS AM, OHLSSON A, SHERMAN PM et al: Meta-analysis of enteral nutrition as primary therapy for active Crohn's disease. Gastroenterology (1995) 108 (4):1056–1067.
   PubMed Web of Science ®Google Scholar
• URSING B, ALM T, BARANY F et al.: A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. Gastroenterology (1982) 83:550–562.
   PubMed Web of Science ®Google Scholar
• COLOMBEL JF, LEMANN M, BOUHNIK Y et al.: A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Gastroenterology (1997) 112:A951.
   Web of Science ®Google Scholar
• SILVERSTEIN MD, LOFTUS EV, SANDBORN WJ et al: Clinical course and costs of care for Crohn's disease: Markov analysis of a population-based cohort. Gastro-enterology (1999) 117:49–57.
   PubMed Web of Science ®Google Scholar
• DEUSCH K, MAUTHE B, REITER C et al: CD4-antibody treatment of inflammatory bowel disease: one year follow-up. Gastroenterology (1993) 104:A691.
   Web of Science ®Google Scholar
• STRONKHORST A, YONG SL, TEN BERGE I et al: CD4antibody treatment in patients with active Crohn's disease: a Phase 1 dose finding study. Gut (1997) 40:320–327.
   PubMed Web of Science ®Google Scholar
• SANDS BE: Novel therapies for inflammatory bowel. Gastroenterol. Clin. North Am. (1 99 9) 28 (2):323–351.
   Google Scholar
• ••A well-written review article covering biologic therapies,newer immunosuppressives, cell adhesion directed therapies and miscellaneous therapies.
   Google Scholar
• WATKINS PE, WARREN BF, STEPHENS S, WARD P, FOULKES R: Treatment of ulcerative colitis in the cotton top tamarin using antibody to tumor necrosis factor. Gut (1997) 40:628–633.
   PubMed Web of Science ®Google Scholar
• MURTHY S, FONDACARO JD, MURTHY NS et al.: Preclinical evaluation of novel elastase and TNF receptor inhibitors and antioxidants in the dextran sulfate (DSS) model of mouse colitis. Gastroenterology (1998) 114:G4282.
   Google Scholar
• TARGAN SR, HANAUER SB, VAN DEVENTER S et al: A short term study of chimeric monoclonal antibody ca2 to tumor necrosis factor alpha for Crohn's disease. N Engl. J. Med. (1997) 337:1029–1035.
   PubMed Web of Science ®Google Scholar
• •Initial study of infliximab which led to approval for clinical use in the United States.
   Google Scholar
• PRESENT DH, RUTGEERTS P, TARGAN SR et al.: Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. (1 99 9) 340 (18):1398–1405.
   Google Scholar
• SEMMLER J, WACHTEL H, ENDRES S: The specific Type IV phosphodiesterase inhibitor rolipram suppressed tumor necrosis factor-alpha production by human mononuclear cells. Int. J. Immunopharmacol. (1993) 15:409–413.
   PubMed Web of Science ®Google Scholar
• BAUDITZ J, HAEMLING J, ORTNER M, LOCHS H, RAEDLER A, SCHREIBER S: Treatment with tumor necrosis factor inhibitor oxpentyfylline does not improve corticos-teroid dependent chronic active Crohn's disease. Gut (1997) 40(4):470–474.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, HANAUER SB: Anti tumor necrosis factor therapy for inflammatory bowel diseases: a review of agents, pharmacology, clinical results and safety. Inflamm. Bowel Dis. (1999) 5(2):119–133
   PubMed Web of Science ®Google Scholar
• FUNAKOSHI K, SUGIMURA K, SASAKAWA T et al.: Study of cytokines in ulcerative colitis. J. Gastroenterol. (1995) 30:60–63.
   Web of Science ®Google Scholar
• SANDS BE: Biologic therapy for inflammatory bowel. Inflamm. Bowel Dis. (1997) 3(2):95–113.
   PubMed Web of Science ®Google Scholar
• •A general overview of biologic therapies with attention to a variety of potential targets.
   Google Scholar
• MONTELONE G, TRAPASSO F, PARRELLO T et al.: Bioactive IL-18 expression is up-regulated in Crohn's disease. J. Immunol. (1999) 163:143–147.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO M, ITO H, KANAZAWA S et al.-interleukin 6 receptor mAB prevents chronic inflammation in SCID mice reconstituted with CD4+ CD45Rbhi T cells. Gastroenterology (1998) 114:A1118.
   Web of Science ®Google Scholar
• MAZZUCCHELLI I, HAUSER C, ZGRAGGEN K et al: Expression of interleukin-8 gene in inflammatory bowel disease is related the histological grade of active inflammation. Am. J. Pathol. (1994) 144:997–1007.
   PubMed Web of Science ®Google Scholar
• LEACH MW, DAVIDSON NJ, FORT MM et al.: The role of IL-10 in inflammatory bowel disease: 'of mice and men'. Toxicol. Pathol (1999) 27(0:123–133.
   PubMedGoogle Scholar
• SANDS BE, BANK S, SNINSKY CA et al.: Preliminary evaluation for safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology (1999) 117:58–64.
   PubMed Web of Science ®Google Scholar
• •A preliminary study of IL-11 in 76 patients which showed promising clinical improvement in patients with CD but with thrombocytosis as a significant side effect.
   Google Scholar
• NEURATH MF, FUSS I, KELSALL BL et al.: Antibodies to 12 abrogate established experimental in mice. J. Exp. Med. (1995) 182:1281–1290.
   PubMed Web of Science ®Google Scholar
• POWRIE F, LEACH MW, MAUZE S et al: Inhibition of Thl responses prevents inflammatory bowel disease in SCID mice reconstituted with CD45Rbhi CD4+ T cells. Immunity (1994) 1:553–562.
   PubMed Web of Science ®Google Scholar
• SCHMITT E, HOEHN P, HUELS C et al.: T helper Type 1 development of naive CD4+ T cells requires the coordi-nate action of interleukin-12 and interferon-gamma and is inhibited by transforming growth factor-beta. Eur. J. Immunol. (1994) 24:793–798.
   PubMed Web of Science ®Google Scholar
• HUSBY S, MESTECKY J, MOLDOVEANU Z et al.: Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding. J. Immunol. (1994) 152:4663–4670.
   Google Scholar
• MURTHY S, FLANIGAN I, OSBORNE BJ et al.: Inflamma-tory bowel diseases: a new wave of therapy. Exp. Opin. Ther. Patents (1998) 8 (7) :785–818.
   Web of Science ®Google Scholar
• ••A recent, comprehensive review of therapeutic patents inboth UC and CD.
   Google Scholar
• BISHOP AE, FACER P et al: Increased expression of cell adhesion molecule P-selectin in active inflammatory bowel disease. Gut (1995) 36:411–418.
   PubMed Web of Science ®Google Scholar
• VAINER B: Role of cell adhesion molecules in inflam- bowel disease. Scand. J. Gastroenterol (1997) 32:401–410.
   PubMed Web of Science ®Google Scholar
• WALLACE JL, HIGA A, MCKNIGHT GW et al.: Prevention reversal of experimental colitis by a monoclonal antibody which inhibits leukocyte adherence. Inflam-mation (1992) 16:343–354.
   PubMed Web of Science ®Google Scholar
• YACYSHYN BR, BOWEN-YACYSHYN MB, JEWELL L et al.: placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology (1998) 114:1133–1142.
   PubMed Web of Science ®Google Scholar
• •A small study which demonstrates promising results with ISIS 2302.
   Google Scholar
• HENRY SP, TEMPLIN MV, GILLETT N et al.: Correlation of and pharmacokinetic properties of a phosphorthioate oligonucleotide designed to inhibit ICAM-1. Toxicol. Pathol. (1999) 27(0:95–100.
   PubMedGoogle Scholar
• MACDONALD TT, PENDER SL: Proteolytic enzymes in bowel disease. Inflamm. Bowel Dis. (1998) 4(2):157–164.
   PubMed Web of Science ®Google Scholar
• •A thorough summary of intestinal proteases with attention to metalloproteinases. Summarises the potential role of proteases in IBD.
   Google Scholar
• SAARIALHO-KERE UK, VAALAMO M, PUOLAKKAINEN P et.: Enhanced expression of matrilysin, collagenase and stromelysin-1 in gastrointestinal ulcers. Am. J. Pathol (1996) 148:519–526.
   Google Scholar
• CHERNEY RJ, WANG L, MEYER DT et al.: Macrocyclic inhibitors of matrix metalloproteinases and TNF-alpha production. Bioorg. Med. Chem. Lett. (1999) 9(9):1279–1284.
   PubMed Web of Science ®Google Scholar
• SU C, WEN X, BAILEY ST et al.: A novel therapy for colitis PPAR-y ligands to inhibit the epithelial inflammatory response. J. Clin. Invest. (1999) 104 (4) :383–389.
   PubMed Web of Science ®Google Scholar
• BAEUERLE PA, BALTIMORE D: NF-KB: ten years after. Cell (1996) 87:13–20.
   PubMed Web of Science ®Google Scholar
• AUPAHN N, DIDONATE JA, ROSETTE C et al.: Immuno- by glucocorticoids: inhibition of NF-KB activity through induction of IKB synthesis. Science (1995) 267:286–290.
   Google Scholar
• NEURATH MF, PETTERSSON S, MEYER ZUM BUSHEN-FELDE KHM, STROBER W: Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-KB abrogates established experi-mental colitis in mice. Nature Med. (1996) 2:998–1004.
   PubMed Web of Science ®Google Scholar
• REINSHAGEN M, EGGER B, PROCACCINO F et al.: Neuropeptides in inflammatory bowel disease: an update. Inflamm. Bowel Dis. (1997) 3:303–312.
   PubMed Web of Science ®Google Scholar
• •A discussion of the potentially pro-inflammatory neuropep-tides and their receptors as potential targets in the therapy of IBD.
   Google Scholar
• WOOD JD, PECK OC, SHARMA HS eta].: A non-peptide-1 (NK-1) receptor antagonist suppresses initiation of acute inflammation in the colon of the cotton-top tamarin model for spontaneous colitis and colon cancer. Gastroenterology (1996) 110:A1047.
   Google Scholar
• WALLACE JL, MCCAFFERTY DM, SHARKEY KA: Lack of effect of a tachykinin receptor antagonist in experimental colitis. Reg. Pept. (1998) 73:95–99.
   PubMedGoogle Scholar
• MALCHOW HA: Crohn's disease and Escherichia colt a approach in therapy to maintain remission of colonic Crohn's disease. J. Clin. Gastroenterol (1997) 25:653–658.
   PubMed Web of Science ®Google Scholar